Hints and tips:
...The activist, known for waging battles at companies including JCPenney, Allergan and Canadian Pacific Railway, is employing the same bare-knuckle tactics at his alma mater, including calling for the removal...
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...The deal is the largest pharmaceutical transaction since AbbVie agreed to buy Allergan for $63bn in 2019 and signals a rebound in mergers and acquisitions following a dip in activity last year, according...
...Its case against Endo, Teva, and Allergan is currently being tried in state court. The settlement payments to New York will begin this summer and continue over the next 17 years....
...A subsequent attempt to slash its tax bill by acquiring Allergan, the Botox maker, and moving its headquarters to Ireland was nixed by the Obama administration....
...Allergan is domiciled in Ireland....
...The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for $63bn, and the largest deal to target a US company in any sector this year....
...(FT) News round-up US regulator clears AbbVie’s $63bn deal for Allergan (FT) KKR posts $4.2bn net loss as investment portfolio hit (FT) Goldman Sachs in talks to buy Invesco holdings (Sky News) Warburg...
...The US pharmaceuticals group AbbVie sealed one of the largest US corporate bond deals on record on Tuesday to finance its $83bn takeover of rival Allergan....
...Yet even with a massive premium, Allergan is being acquired at a price just above half its 2015 peak....
...taxes by capturing Allergan’s Irish tax incorporation....
...Abbvie’s $63bn deal to acquire Allergan, the maker of Botox, is also part of a plan to bolster the company’s pipeline of new drugs before it loses exclusivity on Humira in the US in 2023, when it expects...
...Allergan’s stock climbed 27 per cent to $163.94....
...The rise of Allergan, meanwhile, was masterminded by Mr Saunders....
...Allergan guided to 2019 revenues of between $15.1bn and $15.4bn, compared to the average analyst estimate for $15.2bn....
...Appaloosa currently holds a 0.35 per cent stake in Allergan, according to Eikon data, making it Allergan’s 44th largest shareholder....
...AbbVie borrowed $30bn from investors this month to fund its takeover of rival pharmaceutical company Allergan....
...This week, pharmaceutical company AbbVie borrowed $30bn from bond investors to help fund its $83bn acquisition of Allergan, pushing its total debt outstanding close to $100bn and making it one of the most...
...Much of that was tied to its $84bn takeover of Allergan. Overall, investment banking fees fell 3 per cent in 2019 from a year prior to $101.1bn. Refinitiv estimates it’s a three-year low....
...Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.”...
...And the fees can be eye watering; JPMorgan’s bankers are poised to collect a world record $123m success fee if shareholders of pharma group Allergan vote next month to approve its $63bn sale to rival AbbVie...
...AbbVie announced in June that it plans to acquire Botox maker Allergan for $63bn, as it tries to replenish its pipeline ahead of losing exclusivity on its key drug Humira, for inflammatory diseases, in the...
...Ken Cacciatore, analyst at Cowen, said he believes Allergan’s assets are undervalued but added: “We don’t believe that Allergan will shed what has become a general negative perception unless the portfolio...
...AbbVie last month signalled its intention to buy Allergan, the maker of Botox, for $63bn....
...So far this year, more than $700bn worth of transactions have been agreed in the pharmaceutical and healthcare sector, according to Refinitiv, including AbbVie’s decision to buy the maker of Botox, Allergan...
International Edition